Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit

BACKGROUND: A randomized trial in glioblastoma patients with methylated-MGMT (m-MGMT) found an improvement in median survival of 16.7 months for combination therapy with temozolomide (TMZ) and lomustine, however the approach remains controversial and relatively under-utilized. Therefore, we sought t...

Descripción completa

Detalles Bibliográficos
Autores principales: Castro, Michael, Pampana, Anusha, Alam, Aftab, Parashar, Rajan, Rajagopalan, Swaminathan, Lala, Deepak Anil, Roy, Kunal Ghosh Ghosh, Basu, Sayani, Prakash, Annapoorna, Nair, Prashant, Joseph, Vishwas, Agarwal, Ashish, G, Poornachandra, Behura, Liptimayee, Kulkarni, Shruthi, Choudhary, Nikita Ray, Kapoor, Shweta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Laboratory Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280043/
https://www.ncbi.nlm.nih.gov/pubmed/34101093
http://dx.doi.org/10.1007/s11060-021-03780-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280043/
https://www.ncbi.nlm.nih.gov/pubmed/34101093
http://dx.doi.org/10.1007/s11060-021-03780-0

Ejemplares similares